Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03555019

Nutrition Therapy in the Immature Infant (ImNuT)

Effects of Nutrition Therapy on Growth, Inflammation and Metabolism in Immature Infants; a Double-blind Randomized, Controlled Trial

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
121 (actual)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
48 Hours
Healthy volunteers
Not accepted

Summary

The primary objective of this double-blind randomized study is to assess the effects of an early, enhanced supply of the essential fatty acids (FAs) arachidonic acid (ARA) and docosahexaenoic acid (DHA) on brain maturation, clinical outcomes and quality of growth in immature infants (gestational age \<29 weeks) as compared to standard nutrient supply.

Detailed description

This is a double-blind randomized study. 172 preterm infants with gestational age \< 29 weeks will be enrolled. The intervention group will receive enteral supplementation with essential fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA). The control group will receive standard supplementation with medium-chain triglycerides (MCT-oil). The main hypothesis is that early, enhanced supply of ARA and DHA will improve brain growth and maturation, as compared to standard nutrient supply. Secondary hypotheses are that early, enhanced supply of ARA and DHA will improve quality of growth and cognitive development as well as reduce the frequency of inflammation-related neonatal comorbidities and long-term cardiovascular disease risk. Primary endpoint will be assessed by magnetic resonance imaging (MRI) of the brain at term equivalent age.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFormulaidSupplementation with ARA and DHA
DIETARY_SUPPLEMENTMCT-oilSupplementation with medium chain fatty acids

Timeline

Start date
2018-04-13
Primary completion
2021-05-28
Completion
2029-05-30
First posted
2018-06-13
Last updated
2021-09-08

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT03555019. Inclusion in this directory is not an endorsement.